AMRX vs JAZZ · P/E 44, rev $1.52B vs P/E 1988, rev $2.28B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Jazz Pharmaceuticals PLC (JAZZ) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Latest reported AMRX revenue for 2026-06-30 was $1.52B. Net income was $119.9M. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported JAZZ revenue for 2026-06-30 was $2.28B. Net income was $485.9M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Not investment advice. Open the AMRX and JAZZ stock pages for the full models.
Not investment advice.